Related Experiment Videos
Psoriasis vulgaris treated successfully with mycophenolate mofetil
M G Haufs1, S Beissert, S Grabbe
1Department of Dermatology, University of Münster, Germany.
The British Journal of Dermatology
|April 16, 1998
Summary
Mycophenolate mofetil (MMF), an immunosuppressant, effectively treated severe psoriasis in a patient. This drug significantly reduced psoriasis severity without immediate side effects, offering a new treatment option.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Mycophenolate mofetil (MMF) is an immunosuppressive agent used to prevent organ transplant rejection.
- It functions by inhibiting de novo guanine nucleotide synthesis, crucial for lymphocyte proliferation.
Observation:
- A case study involved a male patient with severe psoriasis.
- The patient was treated with oral Mycophenolate mofetil.
Findings:
- The Psoriasis Area and Severity Index (PASI) score decreased from 22.0 to 11.4 over 5 weeks of MMF therapy.
- The treatment resulted in a significant reduction in psoriasis severity.
Implications:
- Mycophenolate mofetil demonstrates potential as an effective therapeutic alternative for severe psoriasis.
- Further research is warranted to explore MMF's efficacy and safety in broader psoriasis patient populations.